摘要
阿茲海默症（Alzheimer's disease, AD）為一種不可逆、進行性的神經退化性疾病，以認知和行為障礙為主要特徵，是目前最常見的失智症形式，在病人的腦中，會出現不正常的澱粉樣斑塊與神經纖維糾結，導致過度發炎，造成神經細胞壞死。目前治療藥物以乙醯膽鹼酯酶抑制劑（acetylcholinesterase inhibitor）及非競爭性NMDA（N-methyl-D-aspartate）受體拮抗劑兩大類，可改善認知功能，減緩病程的進展，卻不能達到治癒目標。Aducanumab為美國食品藥物管理局於2021年6月核准用於AD引起的輕度認知障礙及早期失智症，可直接針對聚集的β型澱粉樣蛋白，減少澱粉樣蛋白斑塊堆積，本文綜參目前AD藥物治療之相關臨床研究，提供臨床用藥參考。
並列摘要
Alzheimer's disease (AD) is the most frequent cause of dementia and is an irreversible neurological condition characterized by cognitive and behavioral problems. The aberrant amyloid plaques and neurofibrillary tangles in the brains of AD patients cause excessive inflammation and nerve cell death. The medications currently prescribed for therapy include acetylcholinesterase inhibitors and non-competitive N-methyl-D-aspartate (NMDA) receptor antagonists, both of which can enhance cognitive function and delay disease development but do not cure the disorder. The US Food and Drug Administration authorized aducanumab in June 2021 for the treatment of moderate cognitive impairment and early dementia caused by AD. It can target aggregated forms of beta-amyloid and decrease the number of amyloid beta plaques. This article summarizes the findings of the current clinical research on AD therapy and provides a reference for clinical practice.
延伸閱讀
- 徐文俊（2004）。簡介阿茲海默氏症之治療。長期照護雜誌，7(4)，305-316。https://doi.org/10.6317/LTC.200401_7(4).0002
- 王靜修（2005）。阿茲海默症之中醫診治。傳統醫學雜誌，(16)，107-113。https://doi.org/10.30038/JTM.200504.0014
- 廖妙淯、侯承伯、馬景野（2004）。阿爾茲海默氏症（Alzheimer's Disease）的藥物治療及其新進展。當代醫學，(369)，589-593。https://doi.org/10.29941/MT.200407.0017
- 孫瑜（2012）。阿茲海默失智症藥物治療的現況與新進展。應用心理研究，(55)，37-58。https://www.airitilibrary.com/Article/Detail?DocID=15609251-201209-201301070021-201301070021-37-58
- Umegaki, H., Takechi, H., & Dodge, H. H. (2013). Care for Alzheimer's Disease. International Journal of Alzheimer＇s Disease, 2013(), 88-89. https://doi.org/10.1155/2013/516852